Genentech has released a statement to clarify the facts surrounding five people with hemophilia A with inhibitors to factor VIII who have passed away while receiving Hemlibra® (emicizumab-kxwh).
Read Genentech’s press release HERE.
If you have questions or concerns, please reach out to Genentech and/or your physician. Genentech has a Medical Communications line at (800) 821-8590 for patients, concerned community members, and healthcare providers who seek further information.
